Milestone Scientific (MLSS) Q2 FY26 earnings call

Milestone Scientific delivered strong Q2 FY26 results, driven by significant growth in its CompuFlo medical business and strategic advancements in reimbursement and distribution. The company is systematically expanding its Medicare reimbursement footprint and direct sales efforts, while managing costs and investing in high-growth opportunities. Despite anticipated Q3 seasonality, management remains focused on accelerating medical initiatives and expects continued progress in the second half of the year.